Show simple item record

dc.contributor.authorDiro, E
dc.contributor.authorRitmeijer, K
dc.contributor.authorBoelaert, M
dc.contributor.authorAlves, F
dc.contributor.authorMohammed, R
dc.contributor.authorAbongomera, C
dc.contributor.authorRavinetto, R
dc.contributor.authorDe Crop, M
dc.contributor.authorFikre, H
dc.contributor.authorAdera, C
dc.contributor.authorvan Loen, H
dc.contributor.authorTsoumanis, A
dc.contributor.authorAdriaensen, W
dc.contributor.authorHailu, A
dc.contributor.authorvan Griensven, J
dc.date.accessioned2017-10-24T14:00:30Z
dc.date.available2017-10-24T14:00:30Z
dc.date.issued2017-09-13
dc.date.submitted2017-10-18
dc.identifier.citationLong-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trial. 2017 Clin. Infect. Dis.en
dc.identifier.issn1537-6591
dc.identifier.pmid29020217
dc.identifier.doi10.1093/cid/cix807
dc.identifier.urihttp://hdl.handle.net/10144/619029
dc.description.abstractWe have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 months of PSP have been previously reported, supporting PSP effectiveness and safety. However, remaining relapse-free after PSP discontinuation is vital. We now report outcomes and associated factors for a period of upto 2.5 years after initiating PSP, including one year follow-up after PSP discontinuation.
dc.language.isoenen
dc.publisherOxford University Pressen
dc.rightsArchived with thanks to Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of Americaen
dc.titleLong-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trialen
dc.identifier.journalClinical Infectious Diseases : an official publication of the Infectious Diseases Society of Americaen
refterms.dateFOA2019-03-04T13:38:23Z
html.description.abstractWe have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 months of PSP have been previously reported, supporting PSP effectiveness and safety. However, remaining relapse-free after PSP discontinuation is vital. We now report outcomes and associated factors for a period of upto 2.5 years after initiating PSP, including one year follow-up after PSP discontinuation.


Files in this item

Thumbnail
Name:
Diro E - 2017 - Long-term Clinical ...
Size:
647.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record